By Melanie Senior and Christopher Morrison
Sanofi-Synthélabo's bid for Aventis SA is at once defensive and bold. Defensive since Sanofi has only nine months before...
Welcome to In Vivo
Create an account to read this article
Already a subscriber?
Sanofi's attempt to take over Aventis reflects its own status as takeover material for other companies, particularly after it loses the protection of its current shareholder structure. But it is also convinced that its highly productive R&D organization can make much better use of Aventis' R&D expenditures than Aventis has done. Nonetheless, Sanofi, which has been limited in the past by its Franco-centrism, particularly in the key American market, must use the transaction to transform the company into a far more internationally managed and culturally diverse organization. Indeed, for all the European flavor of this deal, it portends an even greater Americanization of the drug business.
By Melanie Senior and Christopher Morrison
Sanofi-Synthélabo's bid for Aventis SA is at once defensive and bold. Defensive since Sanofi has only nine months before...
Create an account to read this article
Already a subscriber?
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.